Evidence map›Paper›PMID 29748305›Full record

SynthesisThe European respiratory journal2018

3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review.

Yibeltal Assefa, Yalemzewod Assefa, Solomon Woldeyohannes, Yohhei Hamada, Haileyesus Getahun

Open access · hybridAbstract readLetterSystematic Review
In one paragraph

Synthesis in The European respiratory journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Adolescent tuberculosis.The Lancet. Child & adolescent health · 2020
    Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Yibeltal AssefaSchool of Public Health, the University of Queensland, Brisbane, Australia.
Yalemzewod AssefaSchool of Public Health, the University of Queensland, Brisbane, Australia.
Solomon WoldeyohannesSchool of Public Health, the University of Queensland, Brisbane, Australia.
Yohhei HamadaGlobal TB Programme, World Health Organization, Geneva, Switzerland.
Haileyesus GetahunGlobal TB Programme, World Health Organization, Geneva, Switzerland.
University of Queensland · AUWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdolescentAntitubercular AgentsChildDrug Administration ScheduleDrug Therapy, CombinationHumansIsoniazidLatent TuberculosisRifampinAntitubercular AgentsIsoniazidRifampin

Identifiers

PMID29748305
PMCPMC6095703
OpenAlexW2801033627

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.